Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$477.89 USD

477.89
285,872

-5.84 (-1.21%)

Updated Jul 9, 2024 04:00 PM ET

After-Market: $478.21 +0.32 (0.07%) 7:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business and momentum in ProCyte One expansion.

Compared to Estimates, Idexx (IDXX) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

IDEXX (IDXX) Q3 Earnings Top Estimates, '23 Sales View Down

by Zacks Equity Research

IDEXX (IDXX) delivers better-than-expected earnings in the third quarter of 2023.

Urmimala Biswas headshot

MedTech Stocks' Q3 Earnings Due on Nov 1: IDXX, EXAS & More

by Urmimala Biswas

MedTech companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how IDXX, EXAS, TNDM and NVST fare this time.

Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IDEXX Laboratories (IDXX) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

IDEXX Laboratories' (IDXX) third-quarter 2023 results are expected to reflect an impressive performance of the CAG segment.

IART vs. IDXX: Which Stock Is the Better Value Option?

by Zacks Equity Research

IART vs. IDXX: Which Stock Is the Better Value Option?

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2024.

Here's Why You Should Hold on to IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) on solid premium instrument placements and upbeat guidance.

Idexx (IDXX) Down 1.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWP

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX) due to the CAG business and the company's execution of its growth strategy.

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Select Medical (SEM) Q2 Earnings Meet, Revenues Rise Y/Y

by Zacks Equity Research

Select Medical's (SEM) Q2 results reflect solid segmental revenues, attributable to higher patient days and outpatient visits. Management projects adjusted EPS of $1.86-$2.03 for 2023.

Idexx (IDXX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

IDEXX (IDXX) Q2 Earnings and Revenues Beat Estimates, View Up

by Zacks Equity Research

IDEXX (IDXX) delivers better-than-expected earnings and revenues in the second quarter of 2023, backed by CAG Diagnostics' recurring revenue growth.

Idexx Laboratories (IDXX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 9.88% and 1.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

IDEXX Laboratories (IDXX) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

IDEXX Laboratories' (IDXX) second-quarter 2023 results are expected to reflect an impressive performance in the CAG segment.

Idexx Laboratories (IDXX) is a Top-Ranked Momentum Stock: Should You Buy?

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Should You Invest in the First Trust Water ETF (FIW)?

by Zacks Equity Research

Sector ETF report for FIW

IDEXX (IDXX) Stock Up 18.4% YTD: Will the Rally Continue?

by Zacks Equity Research

The continued solid demand for veterinary services and benefits from strong execution poise IDEXX (IDXX) well for future growth.

IDEXX (IDXX) Launches First Veterinary Diagnostic Test

by Zacks Equity Research

IDEXX's (IDXX) Cystatin B Test can help veterinary professionals to spot kidney damage before it affects kidney function, which may result in better patient outcomes.

Here's Why You Should Invest in IDEXX (IDXX) Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX) on the strength of the Companion Animal Group business.

Idexx (IDXX) Down 2.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.